ASX:CP1

CannPal Animal Therapeutics (CP1) Stock Price, News & Analysis

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
N/A
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
CP1 stock logo

About CannPal Animal Therapeutics Stock (ASX:CP1)

CannPal Animal Therapeutics Limited, an animal health company, engages in the research and development of plant-based therapeutic products for pets in Australia. It develops CPAT-01, a cannabis-derived pharmaceutical product to provide veterinarians and pet owners to treat pain and inflammation in dogs. The company was incorporated in 2016 and is based in Double Bay, Australia.

CP1 Stock News Headlines

How do animals grow?
Experimenting on animals
Biden replacement revealed?
A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.
Weird Animals
The animals that could be dreaming
How animals reproduce
Elanco Animal Health (NYSE: ELAN)
Biden replacement revealed?
A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.
Animal attacks
The ethics of speciesism
Talking Animals
Animals
Animal Abuse
'Forever chemicals' found in animals around the world
See More Headlines
Receive CP1 Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CannPal Animal Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
Medical
Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$802,623.00
Book Value
A$0.01 per share

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Mr. Layton Patrick Mills
    Founder, MD & Director
  • Dr. Margaret Curtis
    Head of Clinical Devel. and R&D
  • Mr. Baden Maxwell Bowen
    CFO & Company Sec.
  • Dr. Rayson Tan
    Chief Scientific Officer & Member of Advisory Board

This page (ASX:CP1) was last updated on 5/2/2024 by MarketBeat.com Staff

From Our Partners